Charles River Laboratories International (CRL) Equity Average: 2009-2025
Historic Equity Average for Charles River Laboratories International (CRL) over the last 16 years, with Sep 2025 value amounting to $3.4 billion.
- Charles River Laboratories International's Equity Average fell 9.90% to $3.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 billion, marking a year-over-year decrease of 9.90%. This contributed to the annual value of $3.5 billion for FY2024, which is 7.38% up from last year.
- Per Charles River Laboratories International's latest filing, its Equity Average stood at $3.4 billion for Q3 2025, which was up 3.20% from $3.3 billion recorded in Q2 2025.
- Charles River Laboratories International's Equity Average's 5-year high stood at $3.8 billion during Q3 2024, with a 5-year trough of $2.2 billion in Q1 2021.
- Moreover, its 3-year median value for Equity Average was $3.4 billion (2025), whereas its average is $3.4 billion.
- In the last 5 years, Charles River Laboratories International's Equity Average skyrocketed by 32.21% in 2021 and then dropped by 11.03% in 2025.
- Quarterly analysis of 5 years shows Charles River Laboratories International's Equity Average stood at $2.5 billion in 2021, then climbed by 12.93% to $2.8 billion in 2022, then rose by 23.14% to $3.5 billion in 2023, then climbed by 4.93% to $3.6 billion in 2024, then fell by 9.90% to $3.4 billion in 2025.
- Its Equity Average was $3.4 billion in Q3 2025, compared to $3.3 billion in Q2 2025 and $3.3 billion in Q1 2025.